Based on preclinical evidence of dependence on BCL2 and BCL-XL [105–107], several small series have investigated the use of BH3-mimetics in acute lymphoblastic leukemia/lymphoma (ALL). This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.